Recent News Releases
For investor-related news, see our ASX releases here.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Sep 27, 2019• Focuses on Patients Through Disease Awareness Support Activities
MADRID, Spain – 27 September 2019 – Global biotherapeutics leader CSL Behring will host a patient-focused symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 30 September, during the
-
Sep 26, 2019
The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative...
-
Sep 23, 2019
New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit. 23 Sep 2019 Seqirus, a global leader in influenza prevention, has...
-
Sep 17, 2019
This news release is intended for Health Professional media only. 17 Sep 2019 Seqirus, a global leader in influenza prevention, and Laboratoire Arrow, a fast growing player in the pharmaceutical...
-
Sep 11, 2019
St Gallen, 11 September 2019 – Vifor Pharma today announced changes to its management. Dr Klaus Henning Jensen will join the company as Chief Medical Officer and Member of the Executive...
-
Sep 9, 2019
St Gallen, 9 September 2019 – Vifor Pharma announced today that Standard & Poor's (S&P) assigned a BBBcredit rating with stable outlook to Vifor Pharma. This inaugural investment grade credit...
-
Sep 5, 2019Seqirus starts on time delivery of flu vaccines to support NHS immunisation programmes across the UK
This news release is intended for Health Professional media only. Maidenhead, 5 September 2019 Seqirus, a global leader in influenza prevention, announced today that it has started on-time...
-
Sep 4, 2019
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc....
-
Aug 31, 2019
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating...
-
Aug 30, 2019
Summit, NJ – August 30, 2019 Seqirus, a global leader in influenza prevention, today presented data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore from clinical...
-
Aug 22, 2019
Seqirus announced it will feature data in 3 presentations and 24 posters on the company’s adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of...
-
Aug 8, 2019
Strong financial performance in H1 2019 Continued positive performance of all three strategic growth drivers Guidance raised on 2019 net sales and EBITDA On track to achieve Milestone 2020 ZURICH,...
-
Aug 7, 2019
Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination MELBOURNE,...
-
Jul 19, 2019
Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena. Monteriggioni (SI), July 19, 2019 Seqirus, a global...
-
Jul 15, 2019
This news release is intended for business and trade media only. Summit, New Jersey 15 Jul 2019 Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming...
-
Jul 1, 2019- Novel real world evidence for AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] and IDELVION® ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] to be highlighted
Melbourne, Australia - 1 July 2019 - Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation factor...
-
Jun 20, 2019Genoa, Italy
- Eight posters including one oral presentation support ongoing research and clinical experience with Hizentra®, the first and only subcutaneous immunoglobulin (Ig) therapy approved to address...
-
Jun 11, 2019
Vifor Pharma and Evotec to create a jointly-owned drug discovery and development platform for innovative nephrology therapeutics Collaboration brings together Evotec’s best-in-class drug...
-
May 26, 2019
Public-private partnership is intended to safeguard Switzerland’s competitive position in pharmaceutical technologies of the future Zurich and Basel, 26 May 2019 Nanopharmaceutics promises...
-
May 21, 2019
ZURICH, 21 May 2019 – Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun. The study will evaluate the potential of Veltassa® to...
-
May 16, 2019Recipients from the US and Netherlands will be recognized in Marburg, Germany on Friday, 24 May
16 May 2019 Marburg, Germany - 16 May 2019 - Global biotherapeutics leader CSL Behring today announced that the company has named five recipients of the 2019 Professor Heimburger Award for...
-
May 15, 2019Dr. McKenzie will be accountable for leading CSL’s global end-to-end supply chain organization and its accompanying strategy.
15 May 2019 KING OF PRUSSIA, PA – May 15, 2019 - CSL today named Dr. Paul McKenzie, an accomplished global leader with diverse biotechnology experience, as Chief Operating Officer (COO),...
-
May 10, 2019
Veltassa® (patiromer) enables spironolactone for blood pressure management in patients with resistant hypertension and chronic kidney disease by controlling blood potassium levels. ZURICH, 10 May...
-
May 8, 2019
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Sue Mahony and Kim Stratton and to the Board of Directors Confirmation of all members...
-
Apr 25, 2019New vial options deliver on CSL Behring’s heritage of innovation by providing more alternatives to patients
25 Apr 2019 KING OF PRUSSIA, Pa. – 25 April 2019 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial...